4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Exelixis, Inc. (EXEL) operates in the Biotechnology industry and is headquartered in Alameda, United States with about 1,077 employees. Its market capitalization is roughly $14 billion. In the fiscal year ended 2025-12-31, EXEL reported $2.3B in revenue and $783M in net income.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Interactive charts & full statements → Open the EXEL valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $2.3B | $2.2B | $1.8B | $1.6B |
| Gross Profit | $2.2B | $2.1B | $1.8B | $1.6B |
| Operating Income (EBIT) | $893M | $690M | $171M | $202M |
| Net Income | $783M | $521M | $208M | $182M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $611M | $599M | $598M | $568M | $555M | — |
| Gross Profit | $591M | $572M | $579M | $549M | $536M | — |
| Operating Income (EBIT) | $251M | $236M | $256M | $214M | $187M | — |
| Net Income | $210M | $244M | $194M | $185M | $160M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $2.8B | $2.9B | $2.9B | $3.1B | — |
| Total Liabilities | $683M | $704M | $678M | $583M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EXEL viewer.
About TickerBase · Data methodology & sources